Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...

Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.

If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...

We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

The FDA approved Spravato for those battling depression and has seen little to no improvement from two types of ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...